MedTrace Logo

DEDICA (Dose of HEparin During Coronary Angioplasty) Trial

NCT01694459 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2012-09-27

No results posted yet for this study

Summary

International guidelines support the use of a full-dose heparin (anticoagulants) during coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances in angioplasty techniques and the widespread use of pretreatment with two antiplatelet agents.

Thus the investigators designed a study comparing safety and efficacy of standard dose heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty who are on aspirin and clopidogrel at the time of the procedure.

Conditions

  • Stable Angina
  • Angina, Unstable
  • Non-ST Elevation (NSTEMI) Myocardial Infarction

Interventions

DRUG

Low-dose heparin

Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions

DRUG

Standard dose heparin

Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.

Sponsors & Collaborators

  • University of Roma La Sapienza

    collaborator OTHER

  • San Filippo Neri General Hospital

    lead OTHER

Principal Investigators

  • Vincenzo Pasceri, MD · San Filippo Neri Hospital

  • Francesco Pelliccia, MD · University of Roma La Sapienza

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01694459 on ClinicalTrials.gov